GC
WX

Guggenheim Capital’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Guggenheim Capital’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-14,096
Closed -$609K – 3163
2015
Q3 		$609K Buy
14,096
+1,611
+13% +$68K ﹤0.01% 2342
2015
Q2 		$528K Sell
12,485
-1,047
-8% -$44.2K ﹤0.01% 2513
2015
Q1 		$525K Sell
13,532
-559
-4% -$21.5K ﹤0.01% 2514
2014
Q4 		$474K Sell
14,091
-4,181
-23% -$148K ﹤0.01% 2541
2014
Q3 		$640K Sell
18,272
-1,338
-7% -$45.9K ﹤0.01% 2450
2014
Q2 		$645K Sell
19,610
-2,190
-10% -$74.9K ﹤0.01% 2491
2014
Q1 		$804K Sell
21,800
-1,528
-7% -$56.1K ﹤0.01% 2377
2013
Q4 		$896K Sell
23,328
-99,044
-81% -$3.13M ﹤0.01% 2296
2013
Q3 		$3.35M Sell
122,372
-5,870
-5% -$139K 0.01% 1307
2013
Q2 		$2.69M Buy
+128,242
New +$2.5M 0.01% 1345

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Guggenheim Capital's WX Position: Q4 2015 in Review

Guggenheim Capital sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 14,096 shares — an estimated $609K sold.

Guggenheim Capital first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $3.35M in Q3 2013. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Guggenheim Capital reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Guggenheim Capital sold 14,096 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $609K.
  • Guggenheim Capital first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Guggenheim Capital's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $3.35M in Q3 2013.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Guggenheim Capital's 13F filing for Q4 2015, filed 16 Feb 2016.